Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute significantly to the therapeutic activities and that the antitumour effects of SGN-40 depend on Fc interactions.
Oflazoglu
E
E
Department of Preclinical Therapeutics, Seattle Genetics Inc., Seattle, WA 98021, USA.
Stone
I J
IJ
Brown
L
L
Gordon
K A
KA
van Rooijen
N
N
Jonas
M
M
Law
C-L
CL
Grewal
I S
IS
Gerber
H-P
HP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019013:CD40 Antigens / Q000276:immunology*; D045744:Cell Line, Tumor; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D016513:Mice, SCID; D010587:Phagocytosis; D011961:Receptors, Fc / Q000502:physiology*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019013:CD40 Antigens; D011961:Receptors, Fc